Komodo Health Stock Price, Valuation & IPO
Last updated on 9 October 2026Komodo Health is privately held. Its shares are not listed on any public exchange and can only be accessed through private secondary transactions.
Source: AXEVIL investment team
Track Komodo Health Stock Price
We monitor the Komodo Health stock price based on the latest private market data and funding rounds. Since there is no Komodo Health stock symbol on public exchanges yet, we provide a consensus price to help you track your investment.
Komodo Health
Komodo Health is an American healthcare data and AI analytics company, founded in 2014, with offices in New York and San Francisco. Its treatment map covers 330 million Americans; as early as 2020, subscriptions were purchased by 19 out of 20 largest pharmaceutical companies, and today Merck, Novo Nordisk, and Alnylam work with the data. Built on top of the data is the AI agent platform Marmot, which drastically reduces research on real patient data: for Novo Nordisk, the shortest study was completed in one weekend instead of six months, and for Alnylam, reporting that used to take months is now prepared in hours. Merck spent a year building its own AI tools, and then adopted Marmot as its foundation — the first commercial agent is used by approximately 200 marketers and analysts. A round of approximately $200 million from Coatue and Dragoneer took place at a Series E valuation of $3.3 billion, with a total of approximately $514 million raised.
Key Metrics Dynamic
See the performance of Komodo Health's key metrics, based on real market data.
Funding rounds
Key highlights
Where Komodo Health stands today across technology, financials and market traction.
Alnylam: first client Marmot.
A pharmaceutical company started with agents for the commercial department in August 2025. In June 2026, it expanded Marmot company-wide, and reporting that previously took months is now ready in hours.
Novo Nordisk: weekends instead of half a year.
The clinical data team used to spend up to six months on research. With Marmot, the shortest study was completed in one weekend, said company vice president Christopher Blanchette.
Merck: about 200 agent users.
Merck spent a year building AI tools itself, and then took Marmot as a basis and retained agent management. The first commercial agent is already in use by approximately 200 marketers and analysts.
Frequently Asked Questions
Not on a public exchange — Komodo Health is privately held. Shares change hands only in private secondary transactions. AXEVIL structures those as dedicated US special purpose vehicles for accredited investors, subject to availability and to the rules of your jurisdiction.
A private company has no single official share price. AXEVIL's consensus estimate is $51.00 per share as of 9 October 2026. Its most recent round implied a post-money valuation of $3.9B (October 2026).
Komodo Health's most recent funding round valued the company at $3.9B post-money (October 2026) — the latest primary-market measure of what the company is worth. Secondary trades can price its shares above or below that round.
No listing has been announced. AXEVIL does not forecast IPO dates — this page states what has actually been filed or reported, with the date it was last checked.
No. Komodo Health is a private company and its shares are not listed on any public exchange.
No. Komodo Health has no ticker symbol because its shares are not listed on any exchange; a symbol is assigned only at an IPO or direct listing.
Get Updates
Stay informed about Komodo Health stock news and new investment rounds.
Risk disclosure and data sources
Secondary-market prices and investment round data on this page, current and historical, are based on publicly available information and on data from market participants, and are provided for informational purposes only. Axevil Capital strives for accuracy; all prices and valuations are approximate and may fluctuate significantly due to low liquidity and limited access to information. The secondary market for private company shares is illiquid and does not guarantee the ability to buy or sell shares at the displayed price.
Nothing on this page is an offer to sell or a solicitation to buy any security, and it is not investment advice. Private-company shares are illiquid, may be impossible to sell, and the entire amount invested can be lost. Availability depends on your jurisdiction and on accredited-investor status.
Axevil Capital, LLC is a Delaware limited liability company (registration No. 6832739) operating as an investment adviser relying on an exemption from registration, filed with the SEC as an Exempt Reporting Adviser (SEC file No. 802-126907; CRD No. 323970). ERA status means the Company files reports with the SEC but is not a registered investment adviser. The Company is not a broker-dealer and is not a member of FINRA or SIPC.